Elite Pharmaceuticals, Inc. (ELTP)
0.2891
-0.01
(-2.00%)
USD |
OTCM |
Aug 24, 16:00
Elite Pharmaceuticals Enterprise Value : 278.03M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 278.03M |
| August 21, 2026 | 284.39M |
| August 20, 2026 | 287.03M |
| August 19, 2026 | 293.00M |
| August 18, 2026 | 293.54M |
| August 17, 2026 | 298.39M |
| August 14, 2026 | 300.54M |
| August 13, 2026 | 352.79M |
| August 12, 2026 | 354.40M |
| August 11, 2026 | 355.48M |
| August 10, 2026 | 354.51M |
| August 07, 2026 | 355.48M |
| August 06, 2026 | 351.92M |
| August 05, 2026 | 355.37M |
| August 04, 2026 | 359.68M |
| August 03, 2026 | 366.90M |
| July 31, 2026 | 374.76M |
| July 30, 2026 | 368.08M |
| July 29, 2026 | 366.90M |
| July 28, 2026 | 370.56M |
| July 27, 2026 | 381.33M |
| July 24, 2026 | 384.04M |
| July 23, 2026 | 370.56M |
| July 22, 2026 | 368.40M |
| July 21, 2026 | 374.87M |
| Date | Value |
|---|---|
| July 20, 2026 | 381.33M |
| July 17, 2026 | 384.83M |
| July 16, 2026 | 396.41M |
| July 15, 2026 | 370.45M |
| July 14, 2026 | 367.22M |
| July 13, 2026 | 359.79M |
| July 10, 2026 | 363.75M |
| July 09, 2026 | 361.62M |
| July 08, 2026 | 364.10M |
| July 07, 2026 | 358.21M |
| July 06, 2026 | 354.40M |
| July 02, 2026 | 333.94M |
| July 01, 2026 | 354.08M |
| June 30, 2026 | 359.90M |
| June 29, 2026 | 401.47M |
| June 26, 2026 | 401.58M |
| June 25, 2026 | 390.70M |
| June 24, 2026 | 374.44M |
| June 23, 2026 | 365.93M |
| June 22, 2026 | 366.47M |
| June 18, 2026 | 363.77M |
| June 17, 2026 | 373.47M |
| June 16, 2026 | 373.36M |
| June 15, 2026 | 371.85M |
| June 12, 2026 | 341.34M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Nektar Therapeutics | 1.967B |
| Daré Bioscience, Inc. | 6.305M |
| Eton Pharmaceuticals, Inc. | 1.825B |
| ANI Pharmaceuticals, Inc. | 1.938B |
| Corcept Therapeutics, Inc. | 13.00B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 5.911M |
| Revenue (Quarterly) | 32.36M |
| Total Expenses (Quarterly) | 26.44M |
| EPS Diluted (Quarterly) | 0.0052 |
| Gross Profit Margin (Quarterly) | 40.61% |
| Profit Margin (Quarterly) | 18.27% |
| Earnings Yield | 9.10% |
| Operating Earnings Yield | 11.03% |
| Normalized Earnings Yield | 2.802 |